Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Leffers N, et al. Among authors: hoogeboom bn. Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13. Cancer Immunol Immunother. 2009. PMID: 18791714 Free PMC article.
HLA class I alleles and cervical neoplasia.
Visser JT, Hoogeboom BN, Reesink-Peters N, Klip H, Hepkema B, van Velde H, van der Zee AG, Daemen T. Visser JT, et al. Among authors: hoogeboom bn. J Infect Dis. 2003 May 15;187(10):1675-6. doi: 10.1086/374938. J Infect Dis. 2003. PMID: 12721951 No abstract available.
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, Daemen T, van der Zee A. Visser J, et al. Among authors: hoogeboom bn. Int J Cancer. 2006 May 15;118(10):2529-37. doi: 10.1002/ijc.21673. Int J Cancer. 2006. PMID: 16353143 Clinical Trial.
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. Lambeck A, et al. Among authors: hoogeboom bn. Int J Cancer. 2007 Aug 1;121(3):606-14. doi: 10.1002/ijc.22710. Int J Cancer. 2007. PMID: 17415711
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Leffers N, et al. Among authors: hoogeboom bn. Int J Cancer. 2009 Nov 1;125(9):2104-13. doi: 10.1002/ijc.24597. Int J Cancer. 2009. PMID: 19621448 Clinical Trial.
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Vermeij R, et al. Among authors: hoogeboom bn. Int J Cancer. 2012 Sep 1;131(5):E670-80. doi: 10.1002/ijc.27388. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22139992 Clinical Trial.
17 results